Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform

NCT ID: NCT06099665

Last Updated: 2025-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

2626 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-27

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients with definitive or possible severe AS or MR on echocardiogram. These endpoints will also be examined within and between assigned groups according to race, ethnicity, sex, and geography.

The primary question that will be answered:

Do automated alerts sent to clinical providers decrease under-treatment of severe aortic stenosis and severe mitral regurgitation?

The study will compare the rate of clinical follow-up and aortic valve surgery in a control group (no alerts sent) to a treatment group (alerts sent to an appropriate care provider).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis Mitral Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Automated alert

Providers that will receive an automated alert sent via the EHR.

Group Type EXPERIMENTAL

Automated alert

Intervention Type BEHAVIORAL

Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.

Control

Care providers in the control arm will not receive an automated alert.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Automated alert

Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

1. Age \< 18 years
2. Patient had evidence of a prior transcatheter or surgical repair or replacement of the target valve
3. The echocardiogram was ordered by a cardiologist on the MHT or a cardiac surgeon
4. Patient already has a scheduled clinic visit with a member of the MHT or a recent (since the start of the study at that site ) clinic visit with the MHT, or a scheduled transcatheter or surgical VI in the future.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic

INDUSTRY

Sponsor Role collaborator

Tempus AI

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wayne Batchelor, MD

Role: PRINCIPAL_INVESTIGATOR

Director of Interventional Cardiology Inova Heart and Vascular Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Saint Luke's Health System

Kansas City, Missouri, United States

Site Status RECRUITING

OhioHealth

Columbus, Ohio, United States

Site Status NOT_YET_RECRUITING

Bon Secours Mercy Health - Lima Market

Lima, Ohio, United States

Site Status NOT_YET_RECRUITING

Oregon Health and Science University

Portland, Oregon, United States

Site Status NOT_YET_RECRUITING

Vanderbilt

Nashville, Tennessee, United States

Site Status RECRUITING

Bon Secours Mercy Health - Richmond Market

Richmond, Virginia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chris Rogers, BS

Role: CONTACT

(414) 220-4384

Loren Wagner, PhD

Role: CONTACT

(414) 234-0384

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Adnan Chhatriwalla, M.D.

Role: primary

Kevin Stiver, M.D.

Role: primary

Sunny Patel, M.D.

Role: primary

Firas Zahr, M.D.

Role: primary

Brian Lindman, M.D.

Role: primary

Brody Wehman, M.D.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TMPS-Cardio-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The VALVE-AI Trial
NCT07023510 RECRUITING NA